Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2014-04-17 Earnings Release
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 1% confidence The document is explicitly titled "ADOCIA announces first-quarter 2014 results" and presents detailed financial tables for the 3 months ended 03/31/2014, including revenues and cash position. This structure is characteristic of an initial announcement of periodic financial results, which aligns with the definition of an Earnings Release (ER). Although it contains some management commentary, its primary function is the release of period-specific financial figures, distinguishing it from a comprehensive Interim/Quarterly Report (IR) or a full Management Discussion and Analysis (MDA). It is not a transcript (CT), a full annual report (10-K), or a presentation (IP). Q1 2014
2014-04-17 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the company's financial results for the first quarter of 2014 ("résultats du 1er trimestre 2014"). It provides key financial highlights (revenue, cash position) and significant clinical event updates. This structure—a brief announcement focusing on key figures and recent developments for a specific short period—perfectly matches the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a general regulatory filing (RNS). Q1 2014
2014-04-17 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled 'Information relative au nombre d'actions et de droits de vote en date du 31 mars 2014' and explicitly references Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights (gross and net) as of the end of March 2014, with previous months included for comparison. This content directly relates to the official disclosure of voting rights and share capital structure, which falls under the category of official regulatory announcements concerning share structure or voting rights. While it is not a Director's Dealing (DIRS) or a general share issue (SHA), the specific focus on the total number of voting rights aligns best with the general regulatory disclosure category, or potentially a specific voting rights announcement if one existed. Given the provided definitions, this is a mandatory regulatory disclosure regarding the capital structure and voting rights. Since there is no specific code for 'Voting Rights Disclosure' outside of DVA (which is for *results* of a vote), and it is a formal regulatory filing, RNS (Regulatory Filings) is the most appropriate fallback for mandatory, non-standardized regulatory disclosures not covered by other specific codes like 10-K or ER. However, upon re-evaluation, the content is a direct report of the share capital and voting rights count, which is a specific type of mandatory disclosure. If we look closely at the options, DVA is for 'Declaration of Voting Results & Voting Rights Announcements'. While this isn't the *result* of a specific vote, it is an announcement about the *total* voting rights, which is closely related. Given the highly specific nature of the other codes, and the lack of a perfect fit, RNS remains the safest general regulatory filing category. However, if we consider the closest thematic fit among the options, it is a disclosure about the structure underpinning shareholder rights. Since it is a formal, periodic disclosure mandated by regulation (AMF), RNS is the correct classification for mandatory, non-financial periodic reports.
2014-04-15 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and details the positive results from a Phase IIa clinical study for a drug candidate (BioChaperone® Lispro). It provides specific clinical data (PK/PD results, statistical comparisons, endpoints met) and outlines the future clinical development plan, including upcoming Phase IIa trials and regulatory meetings (FDA/EMA). This structure—announcing key scientific/clinical progress via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses purely on clinical trial results and development pipeline updates rather than comprehensive financial performance for a reporting period (like a 10-K or IR), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the format and content (announcing key operational/scientific milestones), ER is the most appropriate fit, as these releases often precede or accompany formal financial reports to highlight operational achievements. Q2 2014
2014-04-09 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces positive Phase IIa clinical trial results for a drug candidate (BioChaperone Lispro). It details key efficacy and safety data, compares it to a competitor product (Humalog), and outlines the next steps in the clinical development plan (Phase IIa dose-escalation study, expected results, and planned meetings with FDA/EMA). This content strongly aligns with an initial announcement of periodic financial/clinical results, focusing on key highlights rather than a comprehensive report. This fits the definition of an Earnings Release (ER), even though the results are clinical rather than purely financial, as ER often covers the most significant periodic operational updates. Since the document is a press release announcing results and future plans, and not a full quarterly/annual report (IR/10-K) or a transcript (CT), ER is the most appropriate classification for a major periodic operational update announcement.
2014-04-09 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that the company, Adocia, confirms its eligibility for the PEA-PME tax scheme based on regulatory criteria (employee count, revenue, balance sheet total). This is a specific corporate announcement regarding regulatory/tax status and company structure compliance, rather than a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a general corporate update that doesn't fit perfectly into the other specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP). Given the nature of the announcement—a specific regulatory/tax status confirmation—it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the tax status is viewed as a financing benefit. However, since it is a press release confirming compliance with a specific government scheme, RNS (Regulatory Filings) serves as the most appropriate general category for non-standard, specific corporate news releases that aren't earnings or management reports.
2014-04-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.